Anti-CD123 CAR T-cell therapy (Southwest Hospital)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD123 CAR T-cell therapy (Southwest Hospital)
Drug Alias NameCD123-targeted CAR-T cells (Southwest Hospital)抗CD123嵌合抗原受体T细胞疗法（西南医院）Anti-CD123-CAR-transduced T cells (Southwest Hospital)
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsAnti-CD123
TargetsInterleukin 3 receptorInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia, MyeloidLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesThe Southwest Hospital of AMU
China Registration ClassN/A

Develop Information

Active CompaniesThe Southwest Hospital of AMU
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid
Inactive IndicationsLeukemia

Other Information

ATC CodeN/A
Related LinksN/A